Search
Displaying 581–590 of 692 for “retinal diseases”
-
Including the Foundation in your will or trust provides an opportunity to give a larger gift than you may be able to give out of your current assets. By leaving a gift to the Foundation, you can help fight blinding diseases today and for the future.
By leaving a lasting gift, you’re helping the Foundation while retaining the full use of your assets to provide for today’s needs.
-
Simple Ways to Leave Your Legacy
Many people who don’t have the resources to make a significant gift during their lifetime choose to leave a meaningful gift in their will. By leaving a gift to the Foundation, you will provide vital support for the research that will soon find an end to vision loss. You can leave a legacy of sight.
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
Join a growing movement of changemakers who are transforming passion into purpose and turning everyday moments into life-changing impact. When you fundraise for the Foundation Fighting Blindness, you accelerate the science that saves sight—for millions.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
Recording Available for Achromatopsia Teleconference Hosted by AGTC, Foundation, and Achroma Corp
Research NewsApplied Genetic Technologies Corporation (AGTC), Achroma Corp, and the Foundation Fighting Blindness hosted a one-hour teleconference on the condition. The call highlighted the difficulties patients have in getting a diagnosis for achromatopsia, the importance of genetic testing, and gene therapy clinical trials underway.
-
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Research NewsBased on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
Stem-Cell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study
Research NewsThe trial is one of the first-ever for a stem-cell-derived therapy for RP.
